Anticoagulation for Subsegmental Pulmonary Embolism in Cancer Patients

Introduction to Anticoagulation Therapy

The American Society of Hematology recommends that cancer patients with subsegmental pulmonary embolism should receive anticoagulation rather than observation alone, despite the very low certainty of evidence supporting this recommendation 1, 2, 3
The European Society of Cardiology recommends managing incidental subsegmental pulmonary embolism in cancer patients the same as symptomatic pulmonary embolism when it involves multiple subsegmental vessels or is associated with proven deep vein thrombosis 4, 5, 6

For initial and short-term treatment (3-6 months), apixaban or rivaroxaban are preferred over low molecular weight heparin (LMWH) based on conditional recommendations from the American Society of Hematology 1, 2, 3
Edoxaban should be considered as an alternative to LMWH in patients without gastrointestinal cancer 4, 5
Rivaroxaban should be considered as an alternative to LMWH in patients without gastrointestinal cancer 4, 5
LMWH remains the anticoagulant of choice for patients with gastrointestinal malignancies due to higher bleeding risk observed with direct oral anticoagulants (DOACs) in this population 4, 5

Dalteparin: 200 IU/kg body weight (maximum 18,000 IU) once daily for 1 month, followed by 150 IU/kg once daily for 5 months 7
Enoxaparin: 1 mg/kg subcutaneously twice daily is the FDA-approved regimen for pulmonary embolism treatment, though 1.5 mg/kg once daily is also approved 7

Initial treatment duration should be 3-6 months for all cancer patients with subsegmental pulmonary embolism 1, 2, 3, 8
Extended anticoagulation beyond 6 months should be offered to patients with active cancer, particularly those with metastatic disease or receiving chemotherapy 4, 5, 8
Continue indefinite anticoagulation or until the cancer is considered cured for patients with ongoing active malignancy 1, 2, 4, 5, 3

Gastrointestinal or gastroesophageal malignancies are a contraindication for DOACs due to higher bleeding risk 4, 5
Severe renal impairment (creatinine clearance <30 mL/min) is a contraindication for DOACs, and LMWH or vitamin K antagonists should be considered as alternatives 9
In severe renal insufficiency (CrCl <30 mL/min), consider unfractionated heparin or reduced LMWH doses due to accumulation risk 10

Both DOACs and LMWH are preferred over warfarin for cancer-associated thrombosis 1, 2, 8, 3
DOACs offer improved efficacy over vitamin K antagonists with similar or lower bleeding rates 1, 2, 3